Ryoji Takazawa

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study).

C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study).

Journal: International urology and nephrology

Published: July 14, 2026

Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma.

Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma.

Journal: Japanese journal of clinical oncology

Published: March 09, 2026

Intrarenal pressure monitoring in retrograde intrarenal surgery for high-infectious risk populations.

Intrarenal pressure monitoring in retrograde intrarenal surgery for high-infectious risk populations.

Journal: World journal of urology

Published: February 05, 2026

Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04).

Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04).

Journal: Japanese journal of clinical oncology

Published: January 02, 2026

Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.

Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.

Journal: The Prostate

Published: December 25, 2025

Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).

Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: December 16, 2025

Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis.

Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis.

Journal: Japanese journal of clinical oncology

Published: November 19, 2025

A Case of Staghorn Calculi Treated by Pyelolithotomy Through a Mini-Pararectal Incision

A Case of Staghorn Calculi Treated by Pyelolithotomy Through a Mini-Pararectal Incision

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: November 06, 2025

Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.

Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: October 01, 2025

Impact of Impaired Renal Function on the Efficacy and Safety of Enfortumab Vedotin Monotherapy in a Multicenter Real-World Cohort of Patients With Metastatic Urothelial Cancer: YUSHIMA Study.

Impact of Impaired Renal Function on the Efficacy and Safety of Enfortumab Vedotin Monotherapy in a Multicenter Real-World Cohort of Patients With Metastatic Urothelial Cancer: YUSHIMA Study.

Journal: Clinical genitourinary cancer

Published: July 29, 2025

Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).

Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 02, 2025

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol.

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol.

Journal: BMJ open

Published: March 25, 2025

Showing 1-12 of 46

Last Updated: 09/26/2026